Not only can this mechanism of mechanoresponsiveness be disrupted by oncogenic activation of KRas, which occurs at the level of ROS sensing, but clinical data further suggest that dysregulation of this pathway at the level of ROS generation (NOX2) and calcium influx (TRPM8) is present in breast cancer patients and predictive of clinical outcome. Here, CYBB is linked to breast carcinoma.